Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people ...

Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...

Losing a son to find out his life saved his sister will forever be the most conflicted day for a Richmond couple. Seven-year-old Skylar was found to have cardiomyopathy, a rare and undiagnosed heart ...

Atrium Therapeutics Inc. has launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics.

Learn more about whether Exact Sciences Corporation or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Atrium Therapeutics launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, ...

New drugs approved by the FDA are prolonging the lives of those affected.

Cardiac specialist Angeliki Asimaki, born with congenital heart defects, suffered a stroke at 36 after her heart stopped for up to 14 seconds due to intermittent AV block. After nine major procedures, ...

The meeting will feature sessions on AI in heart failure, advanced LVAD technologies, cardiac xenotransplantation, and more.

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...

Cian O’Donnell has the same genetic heart condition that claimed the life of his father Aonghus, a CUH cardiothoracic surgeon ...

Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.